Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions

INTRODUCTION: In the SAVOR-TIMI trial, the risk of heart failure (HF) was increased by 27% in T2D patients randomized to the dipeptidyl peptidase-4 inhibitor (DPP4i) saxagliptin. Other studies have provided inconsistent results regarding this association. Herein, we performed a pharmacovigilance ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Fadini, Gian Paolo, Sarangdhar, Mayur, Avogaro, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104265/
https://www.ncbi.nlm.nih.gov/pubmed/29549573
http://dx.doi.org/10.1007/s13300-018-0408-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104265/
https://www.ncbi.nlm.nih.gov/pubmed/29549573
http://dx.doi.org/10.1007/s13300-018-0408-2

Ejemplares similares